Form 4: Akebia Therapeutics Executive Sells Shares

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc., reported a transaction involving the sale of 56,019 shares of common stock on June 29, 2026.

Summary

• Erik Ostrowski, the Senior Vice President, Chief Financial Officer, Chief Business Officer & Treasurer of Akebia Therapeutics, Inc., engaged in a stock transaction.
• The transaction involved the sale of 56,019 shares of common stock on June 29, 2026.
• This sale was an automatic 'sell to cover' to satisfy tax withholding obligations related to the vesting of restricted stock units granted on June 28, 2024.
• The sale was executed under pre-established automatic sell-to-cover instructions made on September 8, 2025, intended to comply with Rule 10b5-1(c) safe harbor provisions.
• Following the transaction, Ostrowski beneficially owns 616,616 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a stock sale can appear negative, the explanation clarifies it's an automatic transaction for tax purposes under a pre-established plan, mitigating concerns about management's confidence.

Positives

• The sale was an automatic 'sell to cover' transaction, indicating it was pre-planned to manage tax liabilities associated with equity compensation, rather than a discretionary sale.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting adherence to established trading policies designed to avoid insider trading concerns.
• The executive still beneficially owns a significant number of shares (616,616) after the transaction.

Negatives

• A notable number of shares (56,019) were sold, which could be perceived negatively by the market if not understood in the context of tax withholding.

Risks

• Potential for misinterpretation of the stock sale by investors as a sign of management's lack of confidence in the company's future prospects, despite it being an automatic tax-related transaction.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Management Comments

• The sale represents an automatic 'sell to cover' transaction to cover tax withholding obligations in connection with the vesting of restricted stock units granted on June 28, 2024.
• The sale was effected pursuant to durable automatic sell-to-cover instructions adopted by the reporting person on September 8, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in their beneficial ownership of company stock. Such transactions, especially those related to tax withholding or pre-arranged trading plans (Rule 10b5-1), are common and do not necessarily indicate a change in management's view of the company's prospects.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the transaction, but the explanation of tax withholding and Rule 10b5-1 compliance should mitigate concerns about insider selling.
• Employees: The transaction relates to equity compensation, which is a common form of employee incentive.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported transaction.

Key Dates

Keywords

Akebia Therapeutics, Form 4, Insider Transaction, Stock Sale, Erik Ostrowski, SEC Filing, Restricted Stock Units, Tax Withholding, Rule 10b5-1